此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effects of Bifidobacterium Longum Subsp. Infantis i18 on Gut Microbiota Development and Health in Early Life (Bifido i18)

2026年11月9日 更新者:DiproBio (Shanghai) Co., Ltd.

Effects of Bifidobacterium Longum Subsp. Infantis i18 Intervention on Early-Life Gut Microbiota Development and Health Outcomes: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Clinical Study

This study aims to evaluate the effects of Bifidobacterium longum subsp. infantis i18 supplementation on symptoms, gut microbiota development, and overall health outcomes in healthy infants and young children in China.

研究概览

研究类型

介入性

注册 (估计的)

455

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Hebei
      • Zhangjiakou、Hebei、中国
        • First Hospital Hebei North University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1秒 至 3年 (孩子)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

-

For the Probiotic and Placebo Groups:

  1. Healthy infants and young children aged 0-36 months at enrollment, born at 37-42 weeks of gestation with a birth weight of 2500-4000 g, receiving formula feeding and/or mixed feeding.
  2. Classified as being at high risk according to the study-defined assessment criteria.
  3. No clinically diagnosed allergic disease at enrollment.
  4. Written informed consent provided by the legal guardian.

For the Observational Reference Group:

  1. Healthy infants aged 0-6 months at enrollment, born at 37-42 weeks of gestation with a birth weight of 2500-4000 g, exclusively breastfed.
  2. Classified as being at high risk according to the study-defined assessment criteria.
  3. No clinically diagnosed allergic disease at enrollment.
  4. Written informed consent provided by the legal guardian.

Exclusion Criteria:

  1. Maternal history of metabolic or infectious diseases.
  2. High-risk pregnancy, or maternal history of alcohol, drug, or other substance abuse during pregnancy.
  3. Antibiotic use within 4 weeks before enrollment.
  4. Probiotic product use within 4 weeks before enrollment; for infants younger than 1 month, any use since birth.
  5. Immunosuppressive therapy before enrollment.
  6. Acute or chronic disease within 4 weeks before enrollment that may significantly affect growth and development.
  7. Congenital malformations or birth defects.
  8. Malnutrition requiring hospitalization.
  9. Known allergy to any component of the study probiotic product.
  10. Participation in another clinical trial or use of any investigational drug within 3 months before screening; for infants younger than 3 months, any such participation or use since birth.
  11. Any other condition considered by the investigator to potentially affect participant safety or interpretation of study data.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂组

Matching placebo without the probiotic intervention

实验性的:益生菌组

Bifidobacterium longum subsp. infantis i18 supplementation.

无干预:Observational Reference Group

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Number of participants with newly reported allergic symptoms (atopic dermatitis/eczema etc.) as assessed with the structured allergy symptom questionnaire
大体时间:From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.

次要结果测量

结果测量
大体时间
Number of participants with newly reported respiratory symptoms (respiratory tract infection etc.) as assessed with the structured respiratory symptom questionnaire
大体时间:From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
Number of participants with newly reported gastrointestinal symptoms (constipation etc.) as assessed with the structured gastrointestinal symptom questionnaire
大体时间:From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
Feeding pattern as assessed with the structured feeding questionnaire
大体时间:From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
Growth and nutritional status: body weight (kg), length/height (cm) and head circumference (cm) measured with a calibrated scale, infantometer/stadiometer and measuring tape, with age- and sex-adjusted Z-scores per WHO Child Growth Standards
大体时间:From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
Gut microbiota composition and diversity: relative abundance (%), alpha diversity and beta diversity in faecal samples assessed by metagenomic sequencing.
大体时间:From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), faecal samples collected at each scheduled study visit.
From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), faecal samples collected at each scheduled study visit.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月9日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2026年11月3日

首先提交符合 QC 标准的

2026年11月9日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • DICT-2026-01-03

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅